Keros Therapeutics, Inc. (KROS) Revenue History
Annual and quarterly revenue from 2018 to present
KROS Revenue Over Time (2018–2025)
KROS Revenue Growth History
2 of 5 years with positive growth- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- +0.0%
- FY2020 revenue growth
- -100.0%
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -100.0%
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- +2251.0%
- FY2025 revenue growth
- +6775.0%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $367K | -99.8% |
| Q4 2025 | $385K | -87.3% |
| Q3 2025 | $14.3M | +3575.8% |
| Q2 2025 | $18.2M | +49002.7% |
| Q1 2025 | $211.2M | +254413.3% |
| Q4 2024 | $3.0M | +2027.3% |
| Q3 2024 | $388K | +4750.0% |
| Q2 2024 | $37K | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
KROS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
KROS Revenue Analysis (2018–2025)
Current Revenue & Growth
As of June 21, 2026, Keros Therapeutics, Inc. (KROS) generated trailing twelve-month (TTM) revenue of $33.2 million, reflecting significant decline in growth of -99.8% year-over-year. The most recent quarter (Q1 2026) recorded $367,000 in revenue, down 4.7% sequentially.
Historical Growth Trajectory
KROS's historical revenue data shows various trends over time. Keros Therapeutics, Inc.'s highest annual revenue of $244.1 million was recorded in 2025, an all-time high.
Revenue by Segment
KROS's revenue is primarily driven by License (84%), and Service, Other (16%). With over half of revenue concentrated in License, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including KRYS (+25.1% YoY), DAWN (+20.6% YoY), and BEAM (+108.0% YoY) — KROS has underperformed the peer group in revenue growth. Compare KROS vs KRYS →
KROS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KROSCurrent | $33M | -99.8% | - | 28.9% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 DAWN | $158M | +20.6% | - | -80.8% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
KROS Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $244.1M | +6775.0% | $242.6M | 99.4% | $70.6M | 28.9% |
| 2024 | $3.5M | +2251.0% | $3.5M | 100.0% | $-210,833,000 | -5939.0% |
| 2023 | $151K | - | $151K | 100.0% | $-169,941,000 | -112543.7% |
| 2022 | $0 | -100.0% | $0 | - | $-114,790,000 | - |
| 2021 | $20.1M | - | $20.1M | 100.0% | $-56,373,000 | -280.5% |
| 2020 | $0 | -100.0% | $-605,000 | - | $-46,657,000 | - |
| 2019 | $10.0M | +0.0% | $-7,348,000 | -73.5% | $-10,563,000 | -105.6% |
| 2018 | $10.0M | - | $-111,000 | -1.1% | $-1,691,000 | -16.9% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
KROS — Frequently Asked Questions
Quick answers to the most common questions about buying KROS stock.
Is KROS's revenue growth accelerating or slowing?
KROS revenue is declining -99.8% year-over-year. TTM revenue fell to $33M, contrasting with the 5-year CAGR of N/A. The reversal reflects either macro headwinds or company-specific challenges.
What is KROS's revenue history from 2018 to 2026?
Keros Therapeutics, Inc. (KROS) revenue history spans 2018 to 2026. TTM revenue as of 2026 is $33M, growing at -99.8% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is KROS's long-term revenue growth rate (CAGR)?
Keros Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -99.8% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for KROS.
Why does KROS's quarterly revenue fluctuate?
KROS quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Keros Therapeutics, Inc.'s revenue data from 2018 to 2026 shows full historical quarterly detail on this page.
How is KROS's revenue distributed by segment?
KROS reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does KROS's revenue compare to industry peers?
Keros Therapeutics, Inc. (KROS) with TTM revenue of $33M and -99.8% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.